Results published in 2026 suggest the liquid supplements were well tolerated and may offer a more convenient way to provide prescribed valine and isoleucine, although the small study size means the findings should be considered exploratory.
Why Are Valine and Isoleucine Used in MSUD?
Maple syrup urine disease affects the body's ability to break down the branched-chain amino acids leucine, isoleucine and valine.
Dietary management is designed to carefully control these amino acids, particularly leucine, while still providing enough nutrition for normal growth and health.
Some people with MSUD are prescribed additional valine and isoleucine to help maintain appropriate blood amino acid concentrations. Traditionally, these supplements may require measuring or preparing powders, adding another task to an already complex dietary treatment routine.
The study used a valine oral solution containing 50 mg/mL and an isoleucine oral solution containing 25 mg/mL. Participants used the liquid valine in place of their usual supplement for 28 days, followed by the liquid isoleucine for another 28 days.
Researchers looked at how well the products were tolerated and accepted, whether participants took the prescribed amounts, and whether blood concentrations of leucine, isoleucine and valine remained stable.
The research has since been completed and results were published in 2026 in the Orphanet Journal of Rare Diseases.
Interestingly, the ClinicalTrials.gov record still displays the older recruitment information. This is a useful reminder that individual research databases do not always update at the same time, and published research may sometimes provide a more complete picture of what has happened since a study was first registered.
What Did Researchers Learn?
The study was intentionally small and focused primarily on whether the ready-to-use supplements were practical and acceptable for children and families.
Researchers reported that the liquid valine and isoleucine supplements were well tolerated. The ready-to-use format also offered potential practical advantages compared with supplements that require preparation before use.
Blood levels of the branched-chain amino acids were monitored throughout the study as part of evaluating whether participants remained metabolically stable while using the new products.
Because only a small number of participants were studied, the researchers did not perform formal statistical comparisons. The results are therefore best understood as early, exploratory evidence rather than proof that one form of supplementation is better than another.
Improving how existing treatment is delivered can also make a meaningful difference. Families managing MSUD may already be balancing medical formula, carefully measured foods, blood monitoring, sick-day plans and additional amino acid supplementation.
A product that reduces measuring, mixing or preparation may make treatment easier to manage at home, school, while travelling or during other parts of everyday life.
What the research does show is continued interest in making MSUD treatment more practical for patients and families.
Ready-to-use products may eventually provide another option for people who require valine and isoleucine supplementation, depending on product availability and recommendations from their metabolic team.
Learn More
Read the published research or explore the original study record:
Read the Published Study Simplifying Supplementation in MSUD: Tolerance and Acceptability of Liquid Valine and Isoleucine Supplements View the Original ClinicalTrials.gov Record NCT06581991About this article: CanPKU+ provides plain-language research information to help our community understand research and developments relevant to rare metabolic disorders.
